{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:11:56Z","timestamp":1792725116732,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan metabolizing enzyme chronically activated in many cancer patients and its expression and activity correlate with a poor prognosis. In fact, it acts as an immune regulator and contributes to tumor-induced immunosuppression by determining tryptophan deprivation and producing immunosuppressive metabolites named kynurenines. These findings made IDO1 an attractive target for cancer immunotherapy and small-molecule inhibitors, such as epacadostat, have been developed to block its enzymatic activity. Although epacadostat was effective in preclinical models and in early phase trials, it gave negative results in a metastatic melanoma randomized phase III study to test the benefit of adding epacadostat to the reference pembrolizumab therapy. However, the reason for the epacadostat failure in this clinical trial has never been understood. Our data suggest that a possible explanation of epacadostat ineffectiveness may rely on the ability of this drug to enhance the other IDO1 immunoregulatory mechanism, involving intracellular signaling function. These findings open up a new perspective for IDO1 inhibitors developed as new anticancer drugs, which should be carefully evaluated for their ability to block not only the catalytic but also the signaling activity of IDO1.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1134551","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:31:27Z","timestamp":1681446687000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1"],"prefix":"10.3389","volume":"14","author":[{"given":"Eleonora","family":"Panfili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Mondanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciriana","family":"Orabona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gargaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Belladonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Suvieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Pallotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2003.10.006","article-title":"The kynurenine pathway of tryptophan degradation as a drug target","volume":"4","author":"Schwarcz","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(03)00072-3","article-title":"Tolerance, DCs and tryptophan: much ado about IDO","volume":"24","author":"Grohmann","year":"2003","journal-title":"Trends Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16086","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme","volume":"289","author":"Pallotta","year":"2022","journal-title":"FEBS J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.immuni.2022.05.013","article-title":"Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication","volume":"55","author":"Gargaro","year":"2022","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.011","article-title":"The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy","volume":"76","author":"Brochez","year":"2017","journal-title":"Eur J Cancer."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (Epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"B9","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1126\/science.360.6389.588","article-title":"A new cancer immunotherapy suffers a setback","volume":"360","author":"Garber","year":"2018","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-030419-033635","article-title":"Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma","volume":"4","author":"Eynde","year":"2020","journal-title":"Annu Rev Cancer Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2077","article-title":"Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells","volume":"12","author":"Pallotta","year":"2011","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16086","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme","volume":"289","author":"Pallotta","year":"2021","journal-title":"FEBS J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e49756","DOI":"10.15252\/embr.201949756","article-title":"Class IA PI3Ks regulate subcellular and functional dynamics of IDO1","volume":"21","author":"Iacono","year":"2020","journal-title":"EMBO Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.156.3.1095","article-title":"Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo","volume":"156","author":"Fallarino","year":"1996","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12954","article-title":"Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1","volume":"21","author":"Albini","year":"2017","journal-title":"J Cell Mol Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.10.033","article-title":"Identification of a 2-propanol analogue modulating the non-enzymatic function of indoleamine 2,3-dioxygenase 1","volume":"158","author":"Albini","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810278105","article-title":"SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis","volume":"105","author":"Orabona","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.01.005","article-title":"A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells","volume":"46","author":"Mondanelli","year":"2017","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830240631","article-title":"Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity","volume":"24","author":"Puccetti","year":"1994","journal-title":"Eur J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/376695a0","article-title":"Identification of a mouse male-specific transplantation antigen, h-y","volume":"376","author":"Scott","year":"1995","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.609490","article-title":"Targeting indoleamine 2,3-dioxygenase in cancer models using the novel small molecule inhibitor NTRC 3883-0","volume":"11","author":"Grobben","year":"2020","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature13323","article-title":"Aryl hydrocarbon receptor control of a disease tolerance defence pathway","volume":"511","author":"Bessede","year":"2014","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/ncomms2874","article-title":"High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway","volume":"4","author":"Volpi","year":"2013","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020121","article-title":"Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase","volume":"196","author":"Frumento","year":"2002","journal-title":"J Exp Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.8.3771","article-title":"Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses","volume":"168","author":"Mellor","year":"2002","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.08.077","article-title":"Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner","volume":"13","author":"Holmgaard","year":"2015","journal-title":"Cell Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/478192a","article-title":"Cancer: Why tumours eat tryptophan","volume":"478","author":"Prendergast","year":"2011","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","article-title":"Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and AhR activation","volume":"33","author":"Liu","year":"2018","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0125-8","article-title":"The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease","volume":"19","author":"Rothhammer","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-Human phase I study of the oral inhibitor of indoleamine 2,3-Dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: Phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and t(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.taap.2017.03.012","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor","volume":"323","author":"Moyer","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1038\/s41467-022-33285-x","article-title":"USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer","volume":"13","author":"Shi","year":"2022","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1719190115","article-title":"Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form","volume":"115","author":"Nelp","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01185","article-title":"Immunosuppressive IDO in cancer: Mechanisms of action, animal models, and targeting strategies","volume":"11","author":"Zhai","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1392","article-title":"Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma","volume":"27","author":"Zhai","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1134551\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:31:30Z","timestamp":1681446690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1134551\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2023.1134551"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1134551","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"article-number":"1134551"}}